Intelligent Bio Solutions Completes Critical Development Milestone In Plans To Add Ketamine And Tramadol To Fingerprint Drug Test
Portfolio Pulse from Benzinga Newsdesk
Intelligent Bio Solutions Inc. (NASDAQ:INBS) has completed a key development milestone in its plans to add ketamine and tramadol to its Intelligent Fingerprinting Drug Screening System. The new assays for testing both drugs have passed the initial design phase and are ready for scale-up and transfer to manufacture in preparation for potential clinical trials. The system is portable, non-invasive, fast, and cost-effective, with applications in various sectors.
September 08, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intelligent Bio Solutions has completed a key development milestone, which could potentially expand the capabilities of its drug screening system. This could increase its market appeal and potentially boost sales.
The successful completion of this development milestone means that INBS is closer to adding ketamine and tramadol to its drug screening system. This could potentially increase the system's market appeal, as it would be able to detect more substances. This could lead to increased sales, which would likely have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100